本页面由Tiger Trade Technology Pte. Ltd.提供服务

Pyxis Oncology, Inc.

1.43
+0.00500.35%
成交量:14.42万
成交额:20.59万
市值:8,872.65万
市盈率:-0.91
高:1.46
开:1.40
低:1.40
收:1.42
52周最高:5.55
52周最低:0.8332
股本:6,226.42万
流通股本:4,115.63万
量比:1.02
换手率:0.35%
股息:- -
股息率:- -
每股收益(TTM):-1.5736
每股收益(LYR):-1.3231
净资产收益率:-87.28%
总资产收益率:-34.33%
市净率:1.29
市盈率(LYR):-1.08

数据加载中...

公司资料

公司名字:
Pyxis Oncology, Inc.
交易所:
NASDAQ
成立时间:
2018
员工人数:
44
公司地址:
321 Harrison Avenue,11th Floor, Suite 1,Boston,Massachusetts,United States
邮编:
02118
电话:
传真:
- -
简介:
Pyxis Oncology, Inc.于2018年6月11日在特拉华州注册成立。该公司是一家临床阶段的肿瘤学公司,专注于开发多模式的下一代疗法组合,以针对难以治疗的癌症并改善患者的生活质量。该公司开发的候选产品的目标是直接杀死肿瘤细胞,并解决癌症造成的潜在病理,使其无法控制的增殖和免疫逃避。

董事

名称
职位
John Flavin
Chairman of the Board
Lara Sullivan
Chief Medical Officer, Chief Executive Officer, President and Director
Darren Cline
Independent Director
Freda Lewis Hall
Independent Director
Jakob Dupont
Independent Director
Michael A. Metzger
Independent Director
Rachel Humphrey
Independent Director
Santhosh Palani
Independent Director
Thomas Civik
Independent Director

股东

名称
职位
Lara Sullivan
Chief Medical Officer, Chief Executive Officer, President and Director
Jitendra Wadhane
Principal Financial Officer and Chief Accounting Officer